Genmab Net Income 2009-2021 | GNMSF

Genmab annual/quarterly net income history and growth rate from 2009 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Genmab net income for the quarter ending September 30, 2021 was $0.141B, a 69.64% increase year-over-year.
  • Genmab net income for the twelve months ending September 30, 2021 was $0.475B, a 43.58% decline year-over-year.
  • Genmab annual net income for 2020 was $0.729B, a 124.5% increase from 2019.
  • Genmab annual net income for 2019 was $0.325B, a 39.24% increase from 2018.
  • Genmab annual net income for 2018 was $0.233B, a 39.11% increase from 2017.
Genmab Annual Net Income
(Millions of US $)
2020 $729
2019 $325
2018 $233
2017 $168
2016 $176
2015 $114
2014 $54
2013 $20
2012 $-84
2011 $-112
2010 $-57
2009 $-67
2008 $-190
2007 $-76
Genmab Quarterly Net Income
(Millions of US $)
2021-09-30 $141
2021-06-30 $50
2021-03-31 $178
2020-12-31 $107
2020-09-30 $83
2020-06-30 $499
2020-03-31 $40
2019-12-31 $221
2019-09-30 $80
2019-06-30 $13
2019-03-31 $11
2018-06-30 $42
2018-03-31 $33
2017-12-31 $121
2017-09-30 $-1
2017-06-30 $45
2017-03-31 $2
2016-12-31 $124
2016-09-30 $28
2016-06-30 $26
2016-03-31 $-2
2015-12-31 $57
2015-09-30 $21
2015-06-30 $2
2015-03-31 $33
2014-12-31 $12
2014-09-30 $27
2014-06-30 $-5
2014-03-31 $18
2013-12-31 $11
2013-09-30 $1
2013-06-30 $-5
2013-03-31 $13
2012-12-31 $-62
2012-09-30 $-10
2012-06-30 $-0
2012-03-31 $-12
2011-12-31 $-8
2011-09-30 $-67
2011-06-30 $-15
2011-03-31 $-21
2010-12-31 $-14
2010-09-30 $-3
2010-06-30 $-16
2010-03-31 $-24
2009-12-31 $12
2009-09-30 $-19
2009-06-30 $-24
2009-03-31 $-36
2008-12-31 $-86
2008-06-30 $-68
2008-03-31 $-42
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $25.881B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.10